Lung Cancer Genetics Study Launches Open-Source Data Platform to Research Community

Core Insights - The Lung Cancer Genetics Study, launched in 2024, aims to enroll 10,000 individuals diagnosed with lung cancer by 2027 and currently has over 1,200 participants, making it one of the most diverse cohorts for lung cancer genetics research [1][4] Group 1: Research Platform and Data Access - An open-source data platform has been launched for the Lung Cancer Genetics Study, allowing researchers to request access to de-identified data from consenting participants [2] - Approved researchers can access a unique lung cancer dataset at no cost through Lifebit's Trusted Research Environment (TRE), which includes germline genotyping and self-reported health data [3] - The platform is designed to eliminate data silos and enhance collaboration among researchers, enabling faster and more impactful discoveries [5][6] Group 2: Patient Engagement and Research Equity - The study emphasizes patient partnership, allowing participants to engage in the data governance process and influence future research [6] - The research environment is secure and compliant with standards such as DoD, NIST, GDPR, and HIPAA, ensuring sensitive data is protected [6] - The initiative aims to create a new model for research equity and access, addressing gaps in lung cancer research funding and participation [7][11] Group 3: Organizational Background - 23andMe Research Institute is a nonprofit organization focused on genetic research and aims to be a significant contributor to scientific advancement [9] - Lifebit is recognized as a leader in federated, secure, and AI-powered health data platforms, managing over 270 million patient records globally [10] - Troper Wojcicki Philanthropies (TWP) has dedicated 30% of its funding over the last 15 years to advancing cancer research, particularly lung cancer, in honor of Susan Wojcicki [11]